36 completed, 5 terminated, 4 unknown, 3 active not recruiting. 54 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 54 | Completed 36, Terminated 5, Unknown 4, Active not recruiting 3, Withdrawn 3, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 5 | Completed 2, Terminated 2, Active not recruiting 1 |
Follow Neoplasms, Fibrous Tissue: new trials by email Literature Review of Neoplasms, Fibrous Tissue trials Research Report on Neoplasms, Fibrous Tissue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DEPART Study at Yale Radiation Therapy - Dupuytren's Contracture | Phase 3 | Not yet recruiting | Yale University | 158 | 2026-11-01 | 2026-10-13 |
| A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism Ersodetug - Tumor Hyperinsulinism (Tumor HI) | Phase 3 | Recruiting | Rezolute | 16 | 2025-04-16 | 2026-09-28 |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin - Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 365 | 2024-09-11 | 2026-11-18 |
| Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma Brigimadlin, Ezabenlimab, Gemcitabine - Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS) | Phase 3 | Withdrawn | Boehringer Ingelheim | 2024-06-27 | 2024-07-17 | |
| Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease) EN3835, Placebo - Plantar Fibromatosis, Ledderhose Disease | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 436 | 2023-11-28 | 2026-10-14 |
| Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis EN3835 - Plantar Fibromatosis | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 145 | 2022-02-14 | 2025-03-21 |
| A Study of AL102 in Patients With Progressing Desmoid Tumors AL102, Placebo - Desmoid, Desmoid Tumor | Phase 2 / Phase 3 | Active not recruiting | Immunome, Inc. | 198 | 2021-09-01 | 2026-06-08 |
| Effectiveness of Splinting After Collagenase Injection Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex], Xiaflex + Hand-Based Custom Orthosis - Dupuytren Contracture, Dupuytren's Disease | Phase 3 | Completed | Foundation for Orthopaedic Research and Education | 80 | 2021-07-12 | 2025-02-26 |
| A Randomized, Double-blind,Phase Ⅲ Study of Liposome Doxorubicin in Desmoid Tumor Liposome doxorubicin, Saline Solution - Desmoid Tumor | Phase 3 | Unknown | Sun Yat-sen University | 72 | 2020-09-29 | 2022-09-30 |
| Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) Nirogacestat oral tablet, Placebo Oral Tablet - Desmoid Tumor, Aggressive Fibromatosis | Phase 3 | Completed | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 142 | 2019-04-17 | 2026-08-20 |
| Ledderhose Disease: Radiotherapy or Not? Radiotherapy, Sham Radiotherapy - Ledderhose Disease | Phase 3 | Active not recruiting | University Medical Center Groningen | 84 | 2018-01-23 | 2024-02-28 |
| Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's collagenase injection, limited palmar fasciectomy - Dupuytren's Disease | Phase 3 | Completed | McMaster University | 22 | 2017-07-08 | 2023-07-18 |
| A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Olaratumab, Doxorubicin, Placebo - Soft Tissue Sarcoma | Phase 3 | Completed | Eli Lilly and Company | 509 | 2015-09-14 | 2025-07-15 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment - Desmoid Fibromatosis | Phase 3 | Completed | National Cancer Institute (NCI) | 87 | 2014-03-21 | 2026-06-24 |
| Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren's Disease Collegenase injection, Needle aponeurotomy - Dupuytren Contracture | Phase 3 | Withdrawn | University of Alberta | 2013-05-01 | 2014-04-08 | |
| Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures XIAFLEX / XIAPEX - Dupuytren's Contracture | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 715 | 2012-09-01 | 2017-10-05 |
| Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Behavioral Dietary Intervention, Compliance Monitoring, Counseling - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | Gynecologic Oncology Group | 1070 | 2012-06-18 | 2018-02-19 |
| Collagenase Option for Reduction of Dupuytren's Contracture in Japan Collagenase Clostridium Histolyticum - Dupuytren's Contracture | Phase 3 | Completed | Asahi Kasei Therapeutics Corporation | 104 | 2012-05-01 | 2017-03-21 |
| Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Acetyl-L-Carnitine Hydrochloride, Placebo, Questionnaire Administration - Fatigue, Malignant Ovarian Mixed Epithelial Tumor | Phase 3 | Withdrawn | Gynecologic Oncology Group | 2012-04-01 | 2014-12-31 |
Showing 20 of 54. Sign in to see all of them.
Liposarcoma (15) · Sarcoma (15) · Fibrosarcoma (14) · Brenner Tumor (13) · Dupuytren Contracture (13) · Histiocytoma, Malignant Fibrous (13) · Hemangiosarcoma (12) · Leiomyosarcoma (11) · Neurofibrosarcoma (11) · Ovarian Neoplasms (11) · Sarcoma, Synovial (10) · Fallopian Tube Neoplasms (8) · Hemangiopericytoma, Malignant (8) · Carcinoma, Ovarian Epithelial (7) · Malignant mesenchymal tumor (6)
Neoplasms by Histologic Type (54) · Neoplasms, Connective Tissue (54) · Neoplasms, Connective and Soft Tissue (54) · Neoplasms (51) · Fibroma (21) · Neoplasms by Site (19) · Neoplasms, Glandular and Epithelial (19) · Endocrine System Diseases (18) · Skin and Connective Tissue Diseases (18) · Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Genital Diseases (17) · Genital Diseases, Female (17) · Genital Neoplasms, Female (17)
Doxorubicin (11) · Paclitaxel (11) · Ifosfamide (9) · Radiotherapy (9) · Carboplatin (8) · Microbial Collagenase (7) · Bevacizumab (5) · Taxes (5) · Cisplatin (4) · Disulfides (4) · Immunoglobulin G (4) · xiapex (4) · Chemotherapy, Adjuvant (3) · Collagenases (2) · Cyclophosphamide (2)
Gynecologic Oncology Group (7) · National Cancer Institute (NCI) (7) · European Organisation for Research and Treatment of Cancer - EORTC (6) · Endo USA Inc., a Keenova Therapeutics Company (5) · Alliance for Clinical Trials in Oncology (1) · Asahi Kasei Therapeutics Corporation (1) · Boehringer Ingelheim (1) · Centre Hospitalier Universitaire de Nice (1) · Children's Oncology Group (1) · Eli Lilly and Company (1) · European Paediatric Soft Tissue Sarcoma Study Group (1) · Foundation for Orthopaedic Research and Education (1) · GOG Foundation (1) · INSYS Therapeutics Inc (1) · Immunome, Inc. (1)
United States (32) · Canada (15) · United Kingdom (14) · Germany (11) · France (10) · Netherlands (9) · Belgium (8) · Spain (8) · Denmark (7) · Japan (6) · Switzerland (6) · Australia (5) · Austria (5) · Italy (5) · South Korea (5)
Veronica Urdaneta, MD, MPPH (2) · A.N. Van Geel, MD (1) · Aaron R Weiss (1) · Achilleas Thoma, MD MSc FRCSC (1) · Andrea Ferrari, MD (1) · Bernadette Brennan, MD (1) · Bernd Kasper, MD (1) · Bruce McGibbon, MD (1) · Clare Tempany, M.D. (1) · David Alberts (1) · David Kushner (1) · David R. Spriggs, MD (1) · David S. Alberts, MD (1) · Deborah K. Armstrong, MD (1)
PMID 37185961, PMID 21941283, PMID 30633128, PMID 16110020, PMID 16368440, PMID 16394300, PMID 16515585, PMID 17264340, PMID 17634494, PMID 17906207, PMID 18430468, PMID 18640939, PMID 19596139, PMID 19726771, PMID 20434400, PMID 21529904, PMID 21967070, PMID 22119995, PMID 22204724, PMID 22204725, PMID 22480131, PMID 22665534, PMID 22954508, PMID 23190833, PMID 23219660, PMID 24470559, PMID 24618336, PMID 24747207, PMID 24942631, PMID 26487588, PMID 26933849, PMID 27020837, PMID 27313184, PMID 27394382, PMID 28391003, PMID 28438473, PMID 28447475, PMID 29450452, PMID 29550184, PMID 30575484, PMID 30954717, PMID 31002578, PMID 31216226, PMID 31722153, PMID 31786124, PMID 32259228, PMID 32702309, PMID 32827353, PMID 33258687, PMID 33548339
U10CA027469 (5), U10CA180868 (5), U10CA098543 (2), U10CA101165 (2), U10CA180830 (2), 2009 (1), 2015 (1), U10CA031946 (1), U10CA081920 (1), U10CA180820 (1), U10CA180821 (1), U10CA180886 (1), UG1CA189867 (1)